POLYTRIM
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYTRIM is an ophthalmic antibiotic solution approved in 1988 for bacterial eye infections. It is a fixed-dose combination small molecule indicated for ocular bacterial infections. The drug delivers topical antimicrobial therapy directly to the eye via drops.
$0.938MPart D
LOE ApproachingWith LOE approaching and minimal Part D penetration ($938K annually), this mature product likely operates with a lean team focused on maintenance and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POLYTRIM offers limited career growth due to its mature LOE-approaching lifecycle and minimal prescriber engagement (14 Part D claims in 2023). Roles focus on revenue protection, managed decline, and planning for generic transition rather than brand-building or expansion.
Brand ManagerField Sales Representative
Worked on POLYTRIM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.